GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

Company Overview - GeneDx Holdings Corp. is an AI-powered genetic-testing company that serves healthcare providers, payers, and research organizations, offering advanced analytics for disease understanding and patient management [7][8] - The company utilizes artificial intelligence and machine learning to provide health intelligence solutions, with its core product being the Centrellis platform, which integrates clinical and genomic data [7][8] Financial Performance - As of October 29, 2025, GeneDx's stock price was $136.54, with a market capitalization of $4.05 billion and a revenue of $402.19 million for the trailing twelve months (TTM) [6] - The stock has shown a significant price change of 84.01% over the past year, and it has returned approximately 107% as of December 9, 2025, outperforming the S&P 500's return of 12.4% [6][10] Recent Transactions - CEO Katherine Stueland sold 2,158 shares on October 29, 2025, for approximately $294,654, which was 38.58% of her remaining direct holdings [2][3] - The transaction involved exercising options on 3,874 underlying shares, with the sale intended to cover tax withholding obligations, indicating it was a "sell-to-cover" transaction rather than a discretionary sale [5][9] Market Context - The timing of Stueland's transaction coincided with a year-to-date stock increase of about 71%, reflecting strong market performance [5] - The healthcare industry is expected to see significant growth, with revenue pools projected to grow at an 8% compound annual growth rate (CAGR) from 2023 to 2028, driven by advancements in software platforms and data analytics [11]